Who is sponsoring SYSUCC-001?

SYSUCC-001 is sponsored by Sun Yat-sen University.

What condition does SYSUCC-001 study?

SYSUCC-001 studies Breast Cancer.

What is the status of SYSUCC-001?

SYSUCC-001 is currently COMPLETED.

Last reviewed 2020-05-27 · How we verify

Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer (SYSUCC-001)

NCT01112826 PHASE3 COMPLETED

The primary objective of this study is to compare disease-free survival (DFS) of patients with triple negative breast cancer randomised to treatment with standard adjuvant chemotherapy alone or to standard adjuvant chemotherapy followed by 1 year of Capecitabine (Xeloda) metronomic therapy.

Details

Lead sponsor	Sun Yat-sen University
Phase	PHASE3
Status	COMPLETED
Enrolment	443
Start date	Fri Apr 23 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Breast Cancer

Interventions

Capecitabine

Countries

China